NCT05529342View on ClinicalTrials.gov

Long-term Follow-up of Study Participant Treated With Lentiviral-Based Genetically Modified Autologous Cell Product ,AGT103-T

Enrolling by invitationOBSERVATIONAL
Enrollment

7

Participants

Timeline

Start Date

August 29, 2022

Primary Completion Date

May 23, 2038

Study Completion Date

September 29, 2038

Conditions
HIV
Interventions
BIOLOGICAL

Gene modified therapy

No investigational cell product will be administered

Trial Locations (2)

20007

Georgetown University, Washington D.C.

20017

Washington Health Institute, Washington D.C.

Sponsors
All Listed Sponsors
lead

American Gene Technologies International Inc.

INDUSTRY

NCT05529342 - Long-term Follow-up of Study Participant Treated With Lentiviral-Based Genetically Modified Autologous Cell Product ,AGT103-T | Biotech Hunter | Biotech Hunter